PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc.

PepGen (PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne ...

PepGen paused its Phase 2 CONNECT2 study of PGN-EDO51 in DMD to review 10 mg/kg cohort data from CONNECT1, expected in Q3 2025. No new safety concerns have emerged and the company aims to refine ...

The US-based biotech said it made the voluntary decision to pause the Phase II CONNECT2-EDO51 trial (NCT06833931) of PGN-EDO51 until it has properly reviewed data from the 10mg cohort in the ...

Dr. Paul Streck, Head of R&D at PepGen, stated that all treatment-related adverse events in CONNECT1 have been mild and the safety profile of PGN-EDO51 appears favorable. The company remains ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...

Paul Streck, MD, Head of R&D, commented, “As of January 23, 2025, all treatment related adverse events in CONNECT1 have been mild, and we believe that the emerging safety profile of PGN-EDO51 ...

Company will temporarily pause CONNECT2 and focus efforts on ongoing CONNECT1-EDO51 study of PGN-EDO51 in DMD, with 10 mg/kg results expected in the third quarter of 2025 No new safety issues have ...

No new safety issues related to PGN-EDO51 have been observed since the Company’s last safety update as of January 23, 2025. “With our 10 mg/kg cohort of CONNECT1 study fully enrolled and data ...